araag2/HINT huggingface dataset:
Clinical trial NCT00003212 (phase 3, status: completed)
Conditions: sarcoma
ICD codes: C96.A, C46.9, C96.22, C46.0, C46.2, C92.31, C92.32
Drugs: doxorubicin hydrochloride, ifosfamide
SMILES: COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        DISEASE CHARACTERISTICS: Histologically proven advanced or metastatic soft tissue sarcoma
        including the following: Malignant fibrous histiocytoma Liposarcoma Rhabdomyosarcoma
        Synovial sarcoma Malignant paraganglioma Fibrosarcoma Leiomyosarcoma Angiosarcoma including
        haemangiopericytoma Neurogenic sarcoma Unclassified sarcoma Mixed mesodermal tumor of the
        uterus Measurable disease with evidence of progression in prior 6 weeks No symptomatic or
        known CNS metastases

        PATIENT CHARACTERISTICS: Age: 15 to 65 Performance status: WHO 0-1 Life expectancy: Not
        specified Hematopoietic: WBC at least 3000/mm3 Neutrophil count greater than 2,000/mm3
        Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater 1.75 mg/dL Albumin at
        least 25 g/L Renal: Creatinine clearance greater than 70 mL/min Cardiovascular: No history
        of uncontrolled cardiovascular disease Other: Fertile women must use effective
        contraception No other severe medical illness including psychosis No prior primary
        malignant tumor except: Adequately treated carcinoma in situ of the cervix Basal cell
        carcinoma

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior
        chemotherapy Endocrine therapy: Not specified Radiotherapy: No radiotherapy to the sole
        index lesion Surgery: Not specified
Clinical trial NCT02806505 (phase 3, status: completed)
Conditions: hepatitis c, chronic
ICD codes: B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, K71.4
Drugs: peginterferon alfa-2a
SMILES: NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Serum hepatitis C virus ribonucleic acid (HCV RNA) quantifiable at greater than (>)
             600 IU/mL

          -  Liver biopsy consistent with chronic hepatitis C infection obtained within 2 years of
             enrollment

          -  Compensated liver disease without cirrhosis

          -  Participants with end-stage renal disease undergoing hemodialysis

          -  Negative serum pregnancy test (for women of childbearing potential) documented within
             the 24-hour period prior to the first dose of study drug

          -  All fertile participants must have been using effective contraception during treatment
             with study drug

        Exclusion Criteria:

          -  Interferon therapy at any previous time

          -  Liver cirrhosis

          -  Signs and symptoms of hepatocellular carcinoma

          -  History or other evidence of decompensated liver disease

          -  Any investigational drug less than or equal to 6 weeks prior to the first dose of
             study drug

          -  History or other evidence of a medical condition associated with chronic liver disease
             other than HCV (e.g., hemochromatosis, autoimmune hepatitis, metabolic liver disease,
             alcoholic liver disease, toxin exposures)

          -  Poorly controlled diabetes

          -  Thyroid dysfunction not adequately controlled

          -  Evidence of severe retinopathy or clinically relevant ophthalmological disorder

          -  Severe hyperparathyroidism defined as intact Parathyroid Hormone (PTH) > 800
             picogram/milliliter (pg/mL)

          -  Therapy with any systemic anti-viral, anti-neoplastic or immunomodulatory treatment ≤
             6 months prior to the first dose of study drug

          -  Acute renal failure

          -  Women with ongoing pregnancy or breast feeding

          -  Positive test at screening for anti-HAV IgM Ab (hepatitis A virus immunoglobulin M
             antibody), hepatitis B surface antigen (HBsAg), anti-HBc (hepatitis B core) IgM Ab,
             anti-HIV (human immunodeficiency virus) Ab
Clinical trial NCT01068678 (phase 3, status: completed)
Conditions: diabetes, diabetes mellitus, type 2
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: insulin degludec, insulin glargine
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Insulin naïve subject (allowed are: previous short term insulin treatment up to 14
             days; Treatment during hospitalisation or during gestational diabetes is allowed for
             periods longer than 14 days)

          -  Current treatment: metformin monotherapy or metformin in any combination with insulin
             secretagogues (sulphonylurea (SU) or glinide), DPP-4 inhibitor,
             alpha-glucosidase-inhibitor (acarbose) with unchanged dosing for at least three months
             prior to Visit 1 with the minimum doses stated: -Metformin: alone or in combination
             (including fixed combination) 1500 mg daily or maximum tolerated dose (at least 1000
             mg daily) -Insulin secretaguogue (sulfonylurea or glinide): minimum half of the daily
             maximal dose according to local labelling -DPP-4 inhibitor: minimum half of the daily
             maximal dose according to local labelling -alpha-glucosidase-inhibitor (acarbose):
             minimum half of the daily maximal dose or maximum tolerated dose

          -  HbA1c 7.0-10.0 % (both inclusive) by central laboratory analysis

          -  Body Mass Index (BMI) below or equal to 45.0 kg/m^2

        Exclusion Criteria:

          -  Use within the last 3 months prior to Visit 1 of: thiazoledinediones, exenatide or
             liraglutide

          -  Cardiovascular disease, within the last 6 months prior to Visit 1, defined as: stroke;
             decompensated heart failure New York Heart Association (NYHA) class III or IV;
             myocardial infarction; unstable angina pectoris; or coronary arterial bypass graft or
             angioplasty

          -  Uncontrolled treated/untreated severe hypertension (systolic blood pressure at least
             180 millimetre (mm) mercury (Hg) and/or diastolic blood pressure at least 100 mmHg)

          -  Pregnancy, breast-feeding, the intention of becoming pregnant or not using adequate
             contraceptive measures according to local requirements (for UK: adequate contraceptive
             measures are defined as established use of oral, injected or implanted hormonal
             methods of contraception, sterilisation, intrauterine device or intrauterine system,
             or consistent use of barrier methods)

          -  Cancer and medical history of cancer hereof (except basal cell skin cancer or squamous
             cell skin cancer)
Clinical trial NCT00053820 (phase 3, status: completed)
Conditions: kidney cancer
ICD codes: D17.71, D30.00, D30.01, D30.02, D41.00, D41.01, D41.02
Drugs: fluorouracil
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed renal cell carcinoma

               -  Advanced metastatic disease that requires treatment

          -  Measurable disease (single bone lesions not included)

          -  No brain metastasis

        PATIENT CHARACTERISTICS:

        Age

          -  18 to 81

        Performance status

          -  WHO 0-1

        Life expectancy

          -  More than 12 weeks

        Hematopoietic

          -  WBC greater than 3,000/mm^3

          -  Platelet count greater than 100,000/mm^3

          -  Hemoglobin greater than 10 g/dL

        Hepatic

          -  Not specified

        Renal

          -  Not specified

        Cardiovascular

          -  No myocardial infarction within the past 6 months

          -  No unstable angina pectoris

        Other

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception during and for at least 6 months
             after study participation

          -  No other concurrent disease or prior malignancy that would preclude study treatments
             or comparisons

          -  No concurrent active infection requiring antibiotics

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  No prior biologic therapy

        Chemotherapy

          -  No prior chemotherapy

        Endocrine therapy

          -  No prior endocrine therapy

          -  No concurrent corticosteroids

        Radiotherapy

          -  At least 4 weeks since prior radiotherapy

        Surgery

          -  Prior resection of the primary tumor recommended but not required

          -  No prior major organ allografts
Clinical trial NCT00377819 (phase 3, status: completed)
Conditions: postmenopausal osteoporosis
ICD codes: N95.0, N95.2
Drugs: alendronate, denosumab (amg 162)
SMILES: COC1=CC2=C(C=C1)C=C(C=C2)[C@H](C)C(O)=O, CC(=O)OC1=CC=CC=C1C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Postmenopausal females 55 yrs or older

          -  Received alendronate therapy for osteoporosis for at least 6 months prior to entry
             into study

          -  Lumbar spine or total hip Bone Mineral Density (BMD) corresponding to T-score ≤ -2 and
             ≥ -4

        Exclusion Criteria:

          -  Vitamin D deficiency

          -  Administration of intravenous bisphosphonate, or

          -  fluoride (except for dental treatment) or

          -  strontium ranelate

          -  Administration of Parathyroid Hormone (PTH) or Parathyroid Hormone (PTH) derivatives
             (eg; teriparatide) within the last year

          -  Administration of any bisphosphonate other than alendronate (ALN) within 1 year of
             screening
Clinical trial NCT00127166 (phase 3, status: completed)
Conditions: exercise induced asthma
ICD codes: Z71.82, J45.990, Z72.3, Y93.A3, Y93.A9, Y93.14, Y93.A1
Drugs: montelukast sodium, salmeterol xinafoate, fluticasone propionate, montelukast matching placebo, salmeterol matching placebo
SMILES: [H][C@@]12C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1, OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1, [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  6-14 year old children with a history of asthma for at least 12 months

          -  must demonstrate airway constriction brought on by exercise

        Exclusion Criteria:

          -  is taking any medications that are not allowed in the study
Clinical trial NCT00220220 (phase 3, status: completed)
Conditions: essential hypertension
ICD codes: I10, O10.02, O10.03, O10.011, O10.012, O10.013, O10.019
Drugs: olmesartan medoxomil, amlodipine
SMILES: CCCC1=NC(=C(N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)C(O)=O)C(C)(C)O, COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(C1=CC=CC=C1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Mean sitting BP of greater than or equal to 140/90-115 mmHg and mean 24h dBP greater
             than or equal to 80 mmHg with at least 30% of daytime readings greater than 85 mmHg
             prior to randomization.

        Exclusion Criteria:

          -  Secondary hypertension of any aetiology;

          -  Any serious disorders which may limit the ability to evaluate the efficacy or safety
             of the test drug(s);

          -  History of myocardial infarction, unstable angina pectoris, percutaneous coronary
             intervention, congestive heart failure, hypertensive encephalopathy, stroke or TIA
             within the last 6 months.
Clinical trial NCT00472303 (phase 3, status: completed)
Conditions: tumor, pain
ICD codes: E88.3, R97.8, C49.A0, C49.A1, C49.A2, C49.A5, C49.A3, N50.82, R07.2, R07.82, R10.13, R10.33, R14.1, R52
Drugs: tapentadol extended release, matching placebo after tapentadol in the titration phase., morphine sulphate controlled release
SMILES: CC[C@H]([C@@H](C)CN(C)C)C1=CC(O)=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
Eligibility criteria:

        Inclusion Criteria

          -  Male and non-pregnant, non-lactating female subjects.

          -  Of at least 18 years of age with chronic malignant tumor-related pain with a mean pain
             intensity (NRS) of 5 points or higher.

          -  Subjects who are opioid-naïve or pretreated with an equianalgesic dose range
             equivalent of up to 160 mg oral morphine per day and are dissatisfied with prior
             treatment.

          -  Women must be postmenopausal, surgically sterile, or practicing or agree to practice
             an effective method of birth control throughout the trial.

          -  Expected course of the disease and the pain that would permit compliance with the
             trial protocol over the entire trial period.

        Exclusion Criteria

        Key Exclusion Criteria:

          -  Subjects will be excluded from the study if they have a history of seizure disorder or
             epilepsy;

          -  known history and/or presence of cerebral tumor or cerebral metastases.

          -  history of alcohol or drug abuse;

          -  uncontrolled hypertension,

          -  clinical laboratory values reflecting severe renal insufficiency,

          -  moderate or severe hepatic impairment,

          -  hepatitis B or C, HIV,

          -  inadequate bone marrow reserve

          -  currently treated with radiotherapy,

          -  pain-inducing chemotherapy,

          -  anti-parkinsonian drugs, neuroleptics, monoamine oxidase inhibitors, serotonin
             norepinephrine reuptake inhibitor (SNRI) or any other analgesic therapy than
             investigational medication or rescue medication during the trial.

          -  selective serotonin reuptake inhibitor (SSRI) treatments are allowed if taken for at
             least 30 days before the screening period of the study at an unchanged dose.
Clinical trial NCT01697956 (phase 3, status: completed)
Conditions: allergic rhinitis
ICD codes: J30.89, J30.9, J30.2, J30.1, J30.5, J30.81
Drugs: bdp, placebo
SMILES: [H][C@@]12C[C@H](C)[C@](OC(=O)CC)(C(=O)COC(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Informed consent/(assent - if applicable)

          -  Male or female subjects 6-11 years of age

          -  General good health

          -  A documented history of PAR to a relevant perennial allergen for a minimum of 12
             months

          -  Other criteria apply

        Exclusion Criteria:

          -  Pregnancy, nursing, or plans to become pregnant or donate gametes

          -  Participation in any investigational drug study within the 30 days preceding the
             Screening Visit 1 (SV1)

          -  Previous participation in a BDP nasal aerosol study as a randomized subject

          -  A known hypersensitivity to any corticosteroid or any of the excipients in the study
             medication formulation

          -  History of physical findings of nasal pathology, including nasal polyps or other
             clinically significant respiratory tract malformations

          -  History of a respiratory infection or disorder within the 14 days preceding the
             Screening Visit 1 (SV1)

          -  Use of any prohibited concomitant medications within the prescribed (per protocol)
             withdrawal periods prior to the Screening Visit 1 (SV1)

          -  Other criteria apply

          -  Current smoker or current user of tobacco products at any time during the study;
             history of smoking or use of tobacco products within the past year
Clinical trial NCT01193153 (phase 3, status: completed)
Conditions: schizoaffective disorder
ICD codes: F25.9, F25.0, F25.1, F25.8
Drugs: placebo, paliperidone palmitate
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1
Eligibility criteria:

        Inclusion Criteria:

          -  DSM-IV diagnosis of schizoaffective disorder

          -  Experiencing an acute exacerbation of psychotic symptoms

          -  A score of >=4 on at least 3 of the following 7 PANSS items: Delusions (P1),
             Hallucinatory behavior (P3), Excitement (P4), Hostility (P7), Tension (G4),
             Uncooperativeness (G8), and Poor Impulse Control (G14)

          -  A score of >=16 on YMRS and/or a score of >=16 on the HAM-D-21

          -  Healthy based on physical examinations, electrocardiogram (ECG), laboratory tests,
             medical history, and vital signs measurements

        Exclusion Criteria:

          -  A primary active mental illness diagnosis other than schizoaffective disorder

          -  Have attempted suicide within 12 months or are at imminent risk of suicide or violent
             behavior

          -  Subjects with first episode of psychosis

          -  Received electroconvulsive therapy in the past 3 months

          -  History of hypersensitivity to or intolerance of paliperidone, risperidone, or 20%
             Intralipid (placebo)

          -  Received long-acting antipsychotic medication within 2 injection cycles

          -  Received therapy with clozapine within 3 months

          -  A history of neuroleptic malignant syndrome

          -  Previous history of lack of response to antipsychotic medication

          -  Subjects receiving therapy with antidepressants or mood stabilizers that has been
             initiated and/or changed in dose <30 days prior to screening

          -  Receiving therapy with carbamazepine

          -  Receiving therapy with monoamine oxidase inhibitors

          -  Pregnant, breast-feeding, or planning to become pregnant
Clinical trial NCT00117598 (phase 3, status: completed)
Conditions: lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: temsirolimus (cci-779), temsirolimus (cci-779), investigator's choice
SMILES: OCC(C)(CO)C(=O)O[C@@H]1CC[C@@H](C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@@H](OC)C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)C[C@H]1OC, OCC(C)(CO)C(=O)O[C@@H]1CC[C@@H](C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@@H](OC)C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)C[C@H]1OC
Eligibility criteria:

        Inclusion Criteria:

          -  Mantle cell lymphoma (MCL) confirmed with histology, immunophenotype, and cyclin D1
             analysis

          -  Received 2 to 7 prior therapies which may include hematopoietic stem cell transplant
             (i.e. induction + consolidation + maintenance)

          -  Prior treatment with an alkylating agent and an anthracycline, rituximab, individually
             or in combination, and status that is at least one of the following:

          -  Primary disease refractory to at least 2 regimens;

          -  Refractory to at least 1 regimen after first relapse;

          -  Refractory or untreated after second or greater relapse;

          -  Refractory to first line and relapsed after second line. Chemotherapy combinations may
             include, but are not limited to: CHOP (Cyclophosphamide, doxorubicin, vincristine,
             prednisone), R-CHOP (Rituximab, Cyclophosphamide, doxorubicin, vincristine,
             prednisone), FCM (Fludarabine, cyclophosphamide, mitoxantrone), R-FCM
             (Rituximab,Fludarabine, cyclophosphamide, mitoxantrone), ICE(Ifosfamide, carboplatin,
             etoposide), DHAP (Dexamethasone, cisplatin, cytarabine) and hyper-CVAD
             (Cyclophosphamide, doxorubicin, vincristine, dexamethasone).

        Exclusion Criteria:

          -  Subjects who are less than or equal to six month from allogeneic hematopoietic stem
             cell transplant and who are on immunosuppressive therapy or have evidence of graft
             versus host disease

          -  Prior investigational therapy within 3 weeks of first dose. Investigational therapy is
             defined as treatment that is not approved for any indication.

          -  Active central nervous system (CNS) metastases, as indicated by clinical symptoms,
             cerebral edema, requirement for corticosteroids and/or progressive growth. (Treated
             CNS metastases must be stable for > 2 weeks prior to Day 1.)
Clinical trial NCT00042562 (phase 3, status: completed)
Conditions: major depressive disorder
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: duloxetine
SMILES: CN(C)CCC[C@]1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  You must be at least 18 years old.

          -  You must have been diagnosed with major depressive disorder.

          -  You must be able to visit the doctor's office once a week to once every 2 weeks for a
             total of 14 weeks

        Exclusion Criteria:

          -  You are a woman and are pregnant or breastfeeding.

          -  You have a current or previous major psychiatric disorder other than depression, such
             as bipolar disorder, schizophrenia, or other psychotic disorder.

          -  You have had a primary diagnosis of an anxiety disorder within the past 6 months.

          -  You have a history of alcohol or drug dependence or abuse within the past 6 months.
Clinical trial NCT00525824 (phase 3, status: completed)
Conditions: hypercholesterolemia, coronary heart disease, atherosclerosis
ICD codes: E78.01, E78.00, Z83.42, I25.10, I25.110, I25.119, I25.111, I25.118, I67.2, I70.90, I70.91, I70.0, I70.1, I70.8, I25.83
Drugs: rosuvastatin (crestor), ezetimibe, simvastatin
SMILES: CC(C)C1=NC(=NC(C2=CC=C(F)C=C2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(=O)O)N(C)S(C)(=O)=O, CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1, CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with with hypercholesterolaemia and CHD or a CHD risk equivalent, clinical
             evidence of atherosclerosis or a Framingham 10-year CHD risk score of >20

          -  Patients will need to sign an informed consent before any visit procedures can be
             performed, including procedures for the optional genetic research and biomarker
             studies.

          -  Patients must be 18 years or older and will be asked to stop taking any current
             cholesterol-lowering medications. Dietary counselling will be provided which will
             include an overview of the Therapeutic Lifestyle Change (TLC) diet the patients will
             be asked to follow

        Exclusion Criteria:

          -  Use of lipid lowering drugs and other prohibited concomitant medications. History of
             statin-induced myopathy, or serious hypersensitivity reaction to other HMG-CoA
             reductase inhibitors (statins), including rosuvastatin, simvastatin and/or a history
             of hypersensitivity to any components of ezetimibe.

          -  Patients considered to be unstable by their physician after the following events:

        a myocardial infarction, recent episode of unstable angina, myocardial revascularisation
        [percutaneous transluminal coronary angioplasty (PTCA), coronary artery bypass graft (CABG)
        surgery or another revascularisation procedure] or a transient ischaemic attack (TIA) or
        stroke and patients awaiting a planned myocardial revascularisation